News - LGC Clinical Diagnostics, a leader in quality solutions for molecular diagnostics, is delighted to announce the launch of the Seraseq® DPYD DNA Mutation Mix. This launch marks LGC Clinical Diagnostics’ entry into the rapidly expanding field of pharmacogenomics, furthering its commitment to personalized medicine. This cutting-edge reference material is designed for developing, validating, and routinely evaluating Next Generation Sequencing (NGS) assays and other molecular assays that detect critical mutations in the DPYD gene.
27 September 2024News - Melbourne, 19 September 2024 -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, today announced a strategic partnership to accelerate the adoption of genomics in agricultural applications.
19 September 2024News - LGC appoints Dr Alexander Zahiri as Executive Vice President & General Manager, Axolabs
26 August 2024News - LGC appoints Marcus Kaeller as Chief Financial Officer
03 June 2024News - Pioneering Cancer Treatments through Enhanced Genomic Profiling in the GenomeMET Project
22 February 2024News - The National Measurement Laboratory and UK NEQAS for Leucocyte Immunophenotyping announce collaboration to improve quality assessment schemes for Chronic Myeloid Leukaemia Minimal Residual Disease testing
25 January 2024News - LGC Biosearch Technologies™ launches a groundbreaking nucleic acid extraction method, sbeadex™ Lightning. This groundbreaking product rapidly delivers high-purity DNA in high-yields, typically achieving results in 5 minutes
15 January 2024